GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperglycemia
Conditions
Hyperglycemia
Trial Timeline
Nov 1, 2006 → May 1, 2007
NCT ID
NCT00393445About GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200
GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200 is a phase 1 stage product being developed by Merck for Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00393445. Target conditions include Hyperglycemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00393445 | Phase 1 | Completed |
Competing Products
9 competing products in Hyperglycemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Exenatide + Insulin | Eli Lilly | Phase 2/3 | 65 |
| Human regular insulin + Insulin lispro + Insulin glargine | Eli Lilly | Phase 3 | 77 |
| Dapagliflozin + Sliding scale insulin | AstraZeneca | Approved | 85 |
| liraglutide + placebo | Novo Nordisk | Pre-clinical | 22 |
| Olanzapine + Ziprasidone | Pfizer | Pre-clinical | 22 |
| NPH insulin plus Complete Insulin Orders + Complete Insulin Orders | Sanofi | Approved | 84 |
| insulin glargine + insulin glargine + insulin glargine | Sanofi | Approved | 84 |
| Lantus® (insulin glargine) | Sanofi | Phase 1 | 32 |
| insulin glargine recombinant + therapeutic insulin | Sanofi | Phase 3 | 76 |